Autolus(US:AUTL) Globenewswire·2026-01-12 12:00Core Insights - Autolus Therapeutics plc reported preliminary unaudited net product revenue from AUCATZYL® sales, with fourth quarter 2025 revenue expected to be approximately $24 million and full year 2025 revenue around $75 million, significantly exceeding expectations [3][6] - The company anticipates 2026 net product revenue for AUCATZYL to be between $120 million and $135 million, driven by a successful launch and positive real-world data [4][6] Commercial Updates - AUCATZYL was successfully launched in the US, with over 60 treatment centers established, and received regulatory approvals in the UK and EU [2][3] - The ROCCA consortium's real-world data confirmed AUCATZYL's high clinical activity and favorable safety profile, which is expected to enhance future growth [2][6] Pipeline Updates - Autolus reported strong initial clinical data from the Phase 1 CATULUS trial in pediatric r/r B-ALL patients, showing a 95.5% overall response rate, and plans to advance to Phase 2 [5][12] - The company is also progressing studies in lupus nephritis and multiple sclerosis, with initial data from the BOBCAT trial expected by the end of 2026 [7][12] Operational Focus - The company aims to optimize manufacturing operations to improve gross margins and drive top-line growth for AUCATZYL in 2026 [8][9] - Autolus has initiated a manufacturing life cycle plan to reduce costs and enhance capacity, with updates expected in mid-2026 [9][10] Financial Outlook - Based on current projections, Autolus expects its cash and marketable securities to fund operations into Q4 2027, supporting ongoing development and commercialization efforts [10]